177Lu-BOT-1712

N/A

Report date: 2025/11/14 17:20:01

Base Information

Drug Name177Lu-BOT-1712

Drug Alias Name177-lutetium-radiolabeled BOT-1712 (BiOrion)second-generation PDGF-beta receptor binding sdAb-177-lutetium conjugate (BiOrion)177Lu-DOTA-MYR-CTX001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateRadiation-emitting products > Nuclides > Lutetium > 177Lu +[5]

Mechanisms of ActionPlatelet-derived growth factor receptor beta modulators

TargetsPlatelet-derived growth factor receptor beta

Therapy Area/IndicationsColonic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBiorion Technologies

China Registration ClassN/A

Develop Information

Active CompaniesBiorion Technologies

Inactive CompaniesN/A

Active IndicationsColonic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A